ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $0

      Shares

      0

      % of Portfolio

      0.00%

      Average Buy Price

      $53.3

      Avg closing price
      Price range

      2 Jefferies Group Sanofi Trades

      Jefferies Group started to build up the position in Sanofi in Q3 2023. Since then they sold 5.33k shares. The investor sold all their shares in Q4 2023 and doesn't own any shares in Sanofi anymore.

      Avg closing price
      Price range
      Sold -5.33k shares Q4 2023
      Avg closing price $48.90
      Price range $43.13 - $54.79
      New holding (+5.33k shares) Q3 2023
      Avg closing price $53.32
      Price range $50.95 - $55.20

      News about Sanofi - ADR and Jefferies Group

      Press Release: Availability of the Q2 2024 Aide-m¨¦moire

      Press Release: Availability of the Q2 2024 Aide-m¨¦moire

      Availability of the Q2 2024 Aide-m¨¦moire Paris, France ¨C June 25, 2024. Sanofi announced that its Q2 2024 Aide-m¨¦moire is available on the "Investors" page o...

      globenewswire.com globenewswire.com, about 1 year ago
      Sanofi - Aventis Groupe: Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

      Sanofi - Aventis Groupe: Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

      Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab)...

      Finanz Nachrichten Finanz Nachrichten, over 1 year ago
      Sanofi - Aventis Groupe: Press Release: Annual General Meeting of April 30, 2024

      Sanofi - Aventis Groupe: Press Release: Annual General Meeting of April 30, 2024

      Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, wit...

      Finanz Nachrichten Finanz Nachrichten, over 1 year ago
      Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia

      Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia

      Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durab...

      RTT News RTT News, over 1 year ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×